Acute Kidney Injury Articles & Analysis: Older
12 news found
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...
ByBayer AG
SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS). The program involved using Oxford Nanopore’s ...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry. The company also reported positive results from a propensity-matched comparison of patients ...
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology. Globally there are 3.5 million patients who are ...
The first evidence of high dose methotrexate related toxicity (HDMTX) in Spain was presented today at Virtual ISPOR Europe 2021, a global conference on healthcare economics and outcomes. Xavier Badia, MD, MPH, PhD of Omakase Consulting S.L. presented the poster titled “Epidemiology and Clinical Management of Patients with Methotrexate Toxicity in Spain Using the Delphi Technique,” ...
Potrero Medical, innovator of the Accuryn Monitoring System, announced the launch of its newest software App for the Accuryn™ Monitor and AccuTab™. The Accuryn Monitoring System includes a revolutionary sensor-integrated foley catheter that provides real-time, actionable information to healthcare providers, enabling them to take important, earlier steps to prevent disease state ...
Potrero Medical, innovator of the Accuryn Monitoring System, a sensory integrated foley catheter that provides real-time, actionable information to health care providers so they can take steps to prevent the progression of critical conditions such as acute kidney injury (AKI), announced that Steve Okland will join Potrero Medical as Chief Commercial Officer. “We are excited to welcome Steve ...
Potrero Medical, innovator of the Accuryn Monitoring System, a sensory integrated foley catheter that provides real-time, actionable information to health care providers so they can take steps to prevent the progression of critical conditions such as acute kidney injury (AKI), announced that Rebecca Lin has been promoted to the role of Chief Strategic Officer. “As we prepare the company ...
Potrero Medical, innovator of the Accuryn Monitoring System, a sensory integrated foley catheter that provides real-time, actionable information to health care providers so they can take steps to prevent critical conditions such as acute kidney injury (AKI), announced that Vanessa Moll, MD, PhD, FCCM, FASA has joined the executive leadership team as its Chief Medical Officer (CMO). Dr. Moll ...
Updated May 12, 2021 to reflect 10 new additions, based on recent analyst reports. We’ve also updated the existing companies on the list to reflect recent business developments. From time to time, medtech analysts will call out companies in the private sector that they believe investors should be keeping tabs on. Here is our ultimate list, compiled from analyst reports, of private ...
Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be ...
Potrero Medical announced today that Jeff Mack is joining its executive leadership team as its Chief Financial Officer (CFO) and will report to CEO Joe Urban. Jeff brings more than 30 years of finance and capital markets experience to Potrero Medical. He also has in-depth knowledge of scaling medical technology startups into significant success stories. “I couldn’t be more thrilled ...